April 8, 2022 7:47am
Lows are looking appetizing, as an upside reversal found support of key levels on Thursday
Pre-open indications: 7 BUYS and 1 Pimp/Pump/Promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
TGIF
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.42% (+142 points), S&P futures are UP +0.32% (+14 points) and NASDAQ futures are UP +0.31% (+45 points)
U.S. stock futures are rising to a positive open on Friday,
European markets advanced,
Asia-Pacific markets were mixed as covid lock-downs affect China although South Korea and Australia were positive
Henry’omics:
The Dow rose +87.06 points, or +0.25% bouncing back on Thursday after two straight days of losses and dropping as much as 300 points earlier in the session while the S&P 500 gained +19.06 or +0.43% and the Nasdaq ticked up +8.48 points or +0.06%.
Despite a mild rebound Thursday and Friday’s early gains, the major averages were headed for a weekly decline.
Economic Data Docket: wholesale inventories report will be released 10 a.m.
RegMed Investors’ (RMi) closing bell: “don’t you want to know the grading of the cell and gene therapy sector instead of looking over many share pricing sites. What justifies the share pricing, it’s NOT investor advocacy? The short-term and near-term pricing “shades” the long-term price targets:” … https://www.regmedinvestors.com/articles/12379
Ebb and flow –
Q2/22 – 2 positive and 3 negative close
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... (35 to date -some dropped a couple added)
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS, POSSIBILITIES and POTENTIALS …
BUY:
Caribou Biosciences (CRBU) closed down -$0.39 to $8.32 with a positive +$0.41 or +4.93% pre-open indication.
BioLife Solutions (BLFS) closed down -$0.05 to $21.91 after Wednesday’s -$0.84, Tuesday’s -$1.40 and last Monday’s +$0.58 with a positive +$1.03 or +4.70% pre-open indication. A new “name” auditor, Grant Thornton after a late 10-K (annual report) and SEC non-compliance action.
Intellia Therapeutics (NTLA) closed down -$.59 to $65.96 after Wednesday’s -$2.61 and Tuesday’s -$6.05) with a positive +$1.13 or +1.71% pre-open indication
Maintaining BUY:
Beam Therapeutics (BEAM) closed down again -$1.43 to $53.37 after Wednesday’s -$1.65, Wednesday’s -$1.65, Tuesday’s -$5.90 and last Monday’s +$2.41 with a positive +$0.62 or +1.16% pre-open indication
CRISPR Therapeutics (CRSP) closed down again -$2.18 to $63.94 after Wednesday’s -$1.36, Tuesday’s -$2.03 and last Monday’s +$3.36 with a positive +$0.56 or +0.88% pre-open indication,
Editas Medicine (EDIT) closed down again -$0.67 to $19.08 after Wednesday’s -$0.58 to $19.75, Tuesday’s -$1.02 and last Monday’s +$1.13 with a positive +$0.53 or +2.78% pre-open indication,
BUY from SELL:
Global Blood Therapeutics (GBT) closed down again -$0.82 to $36.05 after Wednesday’s -$0.52, Tuesday’s +$0.09 and last Monday’s +$1.39 with a positive +$0.41 or +1.14% pre-open indication.
Pimp/Pump and Promote:
Biostage (BSTG) closed down -$0.63 to $5.30 after Wednesday’s -$0.05 with 1,527 shares traded, Tuesday’s +$0.59 with 8,743 shares trading, Monday +$0.49 with 8,809 shares traded and last Friday’s flat with 16 shares traded. WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion? Also, WHY the pump of the volume to gain share appreciation – they have to reverse the multiple private placements (the priciest was $4.71) for a potential/proposed stock offering.
The BOTTOM LINE: The oversold have a good chance to appreciate just from being oversold.
Lower lows greatly outnumbered new highs on Thursday, I believe offering an opportunity – I didn’t write to STAY long.
My version of a relevant quote from IBD, “The major indexes and leading <cell and gene therapy> stocks will often rise on an escalator and come down on an elevator.”
Again, I reiterate, “I’m never totally wrong but, not always wholly right as there is no clear trend ….
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
